Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Regeneus Ltd. ( (AU:CMB) ) has shared an announcement.
Cambium Bio Limited has cleared the FDA regulatory requirements to begin Phase 3 clinical trials for Elate Ocular®, a treatment for moderate to severe dry eye disease. This achievement follows extensive comparability programs and ethics approvals in both Australia and the U.S. The company is now seeking additional financing to initiate the trials, marking a significant step in its mission to provide transformative treatments for patients lacking effective therapies.
More about Regeneus Ltd.
Cambium Bio Limited is a Sydney-based clinical-stage regenerative medicine company specializing in innovative biologics for ophthalmology and tissue repair applications. The company leverages proprietary technology based on human platelet lysate to develop novel therapeutics, with a primary focus on ophthalmology. Its lead product candidate, Elate Ocular®, targets unmet medical needs in treating dry eye disease, while its stem cell platform, Progenza™, is aimed at therapies for knee osteoarthritis and other tissue repair indications.
Average Trading Volume: 5,418
Technical Sentiment Signal: Sell
Current Market Cap: A$3.93M
See more data about CMB stock on TipRanks’ Stock Analysis page.